CDNATL 2019: Supporters

We are pleased that At the Limits events are sponsored by various Industry partners.

Sponsors have not influenced the content or the speaker selection of the independent programmes, nor had, or will have foresight of the presentations.

In 2019 this will include Sponsorship and Grants:


Monday 8th - Wednesday 10th April 2019
The Royal College of Physicians, London, UK

 

Novo Nordisk A/S has supported this International meeting through sponsorship,
and has had no control or input into the educational content of this activity,
nor the logistics functions, ie Travel, Accommodation, Catering or Venues selection.

 

Amgen has supported this International meeting through financial sponsorship
and has had no control or input into the educational content of this activity,
nor the logistics elements, ie travel, accommodation, catering, venue selection or any other aspect of the meeting.

 

           

Vifor Pharma have provided financial support for this international meeting which includes sponsorship of a symposium.
Vifor have only had direct input into the Vifor sponsored symposium. This has included the choice of speakers, honoraria, and design of the agenda.
Vifor products may be mentioned during the symposium. The content of the slides are the speakers’ own.

 

Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. has supported this International meeting through financial sponsorship and has had no control or input into the educational content of this activity, nor the logistics elements, i.e. travel, accommodation, catering, venue selection or any other aspect of the meeting.

 

Servier has supported this International meeting through financial sponsorship and has had no control or input into the educational content of this activity, nor the logistics elements, ie travel, accommodation, catering, venue selection or any other aspect of the meeting. Servier is an independent international pharmaceutical company governed by a non-profit foundation. With a strong international presence in 149 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,700 people and reinvests 25% of its turnover (princeps drugs) in R&D. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs.

 

Leave a comment